STOCKHOLM, Sweden — Regulatory News

13-01-2014 The Herald | HeraldOnline.comComments (0)


Medivir AB (STO:MVIR-B), announces that Idenix Pharmaceuticals, Inc. today released interim data from the ongoing phase II HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir ...

Read more on The Herald |

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top